

INFORMATION DISCLOSURE
CITATIONAttorney Docket No.
12/00004Serial No.
09/622,433

Applicant(s): Nuyen et al.

Sheet 1 of 1

Filing Date: 16 August 2000

Group:

U.S. PATENT DOCUMENTS

Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
<i>N</i>	AA	5,462,726	10/31/95	Lodge	514	558	
<i>N</i>	AB	4,670,262	06/02/87	Battelli et al.	424	131	

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Class	Subclass	Translation	
							YES	NO
<i>N</i>	BA	0 048 149	03/24/82	EPO				X

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)


EXAMINER

DATE CONSIDERED

06/13/2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**Copies of references not provided at the time of this submission.



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14620-012US1	Application No. 09/622,433
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Bastian Nuyen et al.	
		Filing Date May 10, 2002	Group Art Unit

U.S. Patent Documents


Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
N	AA	4,493,796	01/15/1985	Rinehart, Jr.			
N	AB	4,670,262	06/02/1987	Battelli et al.			
N	AC	5,294,603	03/15/1994	Rinehart			
N	AD	5,462,726	10/31/1995	Lodge			
N	AE	5,834,586	11/10/1998	Rinehart et al.			
N	AF	6,034,058	03/07/2000	Rinehart et al.			
N	AG	6,153,731	11/28/2000	Rinehart et al.			
N	AH	6,156,724	12/05/2000	Rinehart et al.			
N	AI	6,710,029	03/23/2004	Rinehart et al.			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
N	AJ	0 048 149 A1 ✓	03/24/1982	EPO				
N	AK	0 393 883 ✓	10/24/1990	EPO				
N	AL	WO 91/04985 ✓	04/18/1991	WIPO				
N	AM	WO 93/00362 ✓	01/07/1993	WIPO				
N	AN	2 102 322 ✓	07/16/1997	Spain			Abstract Only	
N	AO	WO 98/17275 ✓	04/30/1998	WIPO				
N	AP	WO 98/17302 ✓	04/30/1998	WIPO				
N	AQ	WO 99/42125 ✓	08/26/1999	WIPO				
N	AR	WO 01/35974 ✓	05/25/2001	WIPO				
N	AS	WO 01/76616 ✓	10/18/2001	WIPO				
N	AT	WO 02/02596 ✓	01/10/2002	WIPO				
N	AU	WO 02/030441 ✓	04/18/2002	WIPO				
N	AV	WO 03/033013 ✓	04/24/2003	WIPO				


Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
N	AW	Ady-Vago, N. et al., "L-Carnitine as a Protector Against Aplidine Induced Skeletal Muscle Toxicity", <u>Proceedings of the American Association for Cancer Research</u> , Vol. 42, pp. 545 (March, 2001)

Examiner Signature 	Date Considered 05/23/2005
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	


Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14620-012US1	Application No. 09/622,433
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Bastian Nuyen et al.	
		Filing Date May 10, 2002	Group Art Unit
(37 CFR §1.98(b))			

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
W	AX	Bergeron, Raymond J. et al., "Antineoplastic and Antiherpetic Activity of Spermidine Catecholamide Iron Chelators", <u>Biochemical and Biophysical Research Communications</u> , Vol. 121, No. 3, pp. 848-854 (1984)					
W	AY	Broggini, M. et al., "Aplidine Blocks VEGF Secretion and VEGF/VEGF-RI Autocrine Loop in a Human Leukemic Cell Line", <u>11th NCI-EORTC-AACR on New Drugs in Cancer Therapy</u> , Amsterdam (2000), Abstract 214.					
W	AZ	Chapa, A.M. et al., "Influence of Intravenous L-Carnitine Administration in Sheep Preceding an Oral Urea Drench ^{1,2} ", <u>Journal of Animal Science</u> , Vol. 76, No. 11, pp. 2930-2937 (1998)					
W	AAA	Depenbrock, H. et al., "In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells", <u>British Journal of Cancer</u> , Vol. 78, No. 6, pp. 739-744 (1998)					
W	ABB	Erba, E. et al., "Cell cycle phases perturbations induced by new natural marine compounds", <u>Annals of Oncology</u> , Vol. 7, Supplement 1, #283, pp. 82 (1996)					
W	ACC	Faircloth, G. et al., "Aplidine (APL) is a novel marine-derived depsipeptide with in vivo antitumor activity", <u>Proceedings of the American Association for Cancer Research</u> , Vol. 39, #1551, pp. 227 (1998)					
W	ADD	Faircloth, G. et al., "Dehydrodidemnin B (DDB) a new marine derived anti-cancer agent (MDA) with activity against experimental tumor models" and "Biological activity of thiocoraline. A new depsipeptide from a marine micromonospora", <u>Annals of Oncology</u> , Vol. 7, Supplement 1, #111 and #112, pp. 34 (1996)					
W	AEE	Faircloth, G. et al., "Preclinical characterization of Aplidine (APD), a new marine anticancer depsipeptide (MADEP)", <u>Proceedings of the American Association for Cancer Research</u> , Vol. 38, #692, pp. 103 (1997)					
W	AFF	Faircloth, G. et al., "Preclinical development of aplidine, a novel marine-derived agent with potent antitumor activity", <u>Annals of Oncology</u> , Vol. 9, Supplement 2, #129, pp. 34 (1998)					
W	AGG	Faircloth, G. et al., "Schedule-dependency of aplidine, a marine depsipeptide with antitumor activity", <u>Proceedings of the American Association for Cancer Research</u> , Vol. 40, #2612, pp. 394-395 (1999)					
W	AHH	Geldof, Albert A. et al., "Cytotoxicity and neurocytotoxicity of new marine anticancer agents evaluated using in vitro assays", <u>Cancer Chemother. Pharmacol.</u> , Vol. 44, pp. 312-318 (1999)					
W	AII	Genin, Michael J. et al., "Synthesis and Crystal Structure of a Peptidomimetic Containing the (R)-4, 4-Spiro Lactam Type-II β -Turn Mimic", <u>Journal of Organic Chemistry</u> , Vol. 58, No. 8, pp. 2334-2337 (1993)					
W	AJJ	Gomez-Fabre, P.M. et al., "Polamine contents of human breast cancer cells treated with the cytotoxic agents chlorpheniramine and dehydrodidemnin B", <u>Cancer Letters</u> , Vol. 113, Nos. 1, 2, pp. 141-144 (1997)					
W	AKK	Jimeno et al., "A Correlation of Selective Antitumor Activities of the Marine-Derived Compound Aplidine Using Different Models", <u>10th NCI-EORTC-AACR Symposium on Molecular Targets and Cancer Therapeutics</u> , Washington (1999), Abstract 311.					
W	ALL	Jou, Gemma et al., "Total Synthesis of Dehydrodidemnin B. Use of Uronium and Phosphonium Salt Coupling Reagents in Peptide Synthesis in Solution", <u>Journal of Organic Chemistry</u> , Vol. 62, No. 2, pp. 354-366 (1997)					
W	AMM	Lobo, C. et al., "Effect of Dehydrodidemnin B on Human Colon Carcinoma Cell Lines", <u>Anticancer Research</u> , Vol. 17, No. 1A, pp. 333-336 (1997)					


Examiner Signature 	Date Considered 06/13/2005
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14620-012US1	Application No. 09/622,433
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Bastian Nuyen et al.	
		Filing Date May 10, 2002	Group Art Unit

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
~	ANN	Luber-Narod, J. et al., "In Vitro Safety Profile of Aplidine, A Marine Natural Product with Chemotherapeutic Potential", <u>Proceedings of the AACR</u> , Vol. 42, Abstract 374, March 2001.					
~	AOO	Mastbergen, S.C. et al., "Cytotoxicity and neurocytotoxicity of aplidine, a new marine anticancer agent evaluated using in vitro assays", <u>Annals of Oncology</u> , Vol. 9, Supplement 2, #131 (1998)					
~	APP	Montgomery, D.W. et al., "Didemnin B Alters the Specific Binding of Prolactin to Human Lymphocytes and Decreases the Circulating Level of Prolactin in Mice", <u>Federal Proceedings</u> , Vol. 44, No. 3, pp. 634, #1311 (1985)					
~	AQQ	Montgomery, David W. et al., "Didemnin B: A New Immunosuppressive Cyclic Peptide with Potent Activity In Vitro and In Vivo", <u>Transplantation</u> , Vol. 40, No. 1, pp. 49-56 (1985)					
~	ARR	Nuijen, B. et al., "Pharmaceutical development of anticancer agents derived from marine sources", <u>Anti-Cancer Drugs</u> , Vol. 11, pp. 793-811 (2000)					
~	ASS	Raymond, Eric et al., "Preliminary Results of a Phase I and Pharmacokinetic Study of Aplidine Given as a 24-hour Infusion Every 2 Weeks in Patients With Solid Tumors and Non Hodgkin's Lymphomas", <u>Proceedings of the American Association for Cancer Research</u> , Vol. 41, #3886 (2000)					
~	ATT	Rinehart, K., "Didemnin and its Biological Properties", <u>Escom</u> , pp. 626-631 (1987).					
~	AUU	Rinehart, Kenneth L. et al., "Biologically Active Peptides and Their Mass Spectra", <u>Pure and Applied Chemistry</u> , Vol. 54, No. 12, pp. 2409-2424 (1982)					
~	AVV	Rinehart, Kenneth L. et al., "Didemnins and Tunichlorin: Novel Natural Products from the Marine Tunicate <i>Trididemnum Solidum</i> ", <u>Journal of Natural Products</u> , Vol. 51, No. 1, pp. 1-21 (1988)					
~	AWW	Rinehart, Kenneth L. et al., "Total Synthesis of Didemnins A, B and C ^{1,2} ", <u>Journal of the American Chemical Society</u> , Vol. 109, No. 22, pp. 6846-6848 (1987)					
~	AXX	Rinehart, Kenneth L., Jr. et al., "Antiviral and antitumor compounds from tunicates ^{1,2} ", <u>Federation Proceedings</u> , Vol. 42, No. 1, pp. 87-90 (1983)					
~	AYY	Rinehart, Kenneth L., Jr. et al., "Didemnins: Antiviral and Antitumor Depsipeptides from a Caribbean Tunicate", <u>Science</u> , Vol. 212, No. 4497, pp. 933-935 (1981)					
~	AZZ	Rinehart, Kenneth L., Jr. et al., "Structure of the Didemnins, Antiviral and Cytotoxic Depsipeptides from a Caribbean Tunicate ¹ ", <u>Journal of the American Chemistry Society</u> , Vol. 103, No. 7, pp. 1857-1859 (1981)					
~	AAAA	Sakai, Ryuichi et al., "Structure - Activity Relationships of the Didemnins ^{1,2} ", <u>Journal of Medicinal Chemistry</u> , Vol. 39, No. 14, pp. 2819-2834 (1996)					
~	ABBB	Seebach, Dieter et al., "Alkylation of Amino Acids without Loss of the Optical Activity: Preparation of α -Substituted Proline Derivatives. A Case of Self-Reproduction of Chirality ^{1,2} ", <u>Journal of the American Chemical Society</u> , Vol. 105, No. 16, pp. 5390-5398 (1983)					
~	ACCC	Urdiales, Jose L. et al., "Antiproliferative effect of dehydroididemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates", <u>Cancer Letters</u> , Vol. 102, Nos. 1,2, pp. 31-37 (1996)					
~	ADDD	Vervoort, Helene et al., "Tamandarins A and B: New Cytotoxic Depsipeptides from a Brazilian Ascidian of the Family Didemnidae", <u>The Journal of Organic Chemistry</u> , Vol. 65, No. 3, pp. 782-792 (2000)					

Examiner Signature 	Date Considered 06/23/2005
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14620-012US1	Application No. 09/622,433
		Applicant Bastian Nuyen et al.	
	Filing Date May 10, 2002	Group Art Un	



U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
<i>W</i>	AA	6,030,943	02/29/2000	Crumb et al.			

Foreign Patent Documents or Published Foreign Patent Applications							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation
							<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<i>W</i>	AB	WO 2004/080421 A2	09/23/2004	WIPO			

Examiner Signature <i>David Chen</i>	Date Considered <i>06/23/2005</i>
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	